This bill aims to prevent discrimination against entities participating in the federal 340B Drug Pricing Program by health insurance issuers, pharmacy benefit managers, and other third-party payers or their agents. Specifically, it prohibits these parties from imposing different terms or conditions on entities based on their participation in the 340B program or the fact that the drug is covered by the program. The bill ensures that covered entities enrolled in or eligible for the 340B program, as well as their contract pharmacies dispensing 340B drugs to patients, are not subjected to restrictions or requirements that differ from those applied to other entities, such as participation in standard or preferred pharmacy networks or reduced reimbursement amounts for 340B covered drugs.

The bill includes an insertion of a new section, 415:15-a, into RSA 415, which outlines the prohibition of discriminatory practices based on participation in the 340B program. There are no deletions indicated in the provided text. The act was approved on July 3, 2024, and is set to take effect on September 1, 2024, which is 60 days after its passage.